As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm.
The company that makes tagraxofusp has requested that NICE pause this appraisal. This is because it is in the process of merging with another company. As such technical engagement will not take place at this time and the appraisal committee meeting will not be in May 2021 as previously scheduled.